A kan koma-baya na saurin cigaban masanin magani duniya, yana da matukar muhimmanci a fahimci ci gaban ci gaban masana'antu da samfuran kayayyakin masana'antu. A baya can, mafi yawan lokuta na tasiri a waje (Medtech girma 100, Manyan na'urori 100, na'urorin likitoci 25, da sauransu) ba su haɗa da kamfanoni na kasar Sin a cikin ƙididdigar su ba. Saboda haka, Siyu Medtech ya kirkiro jerin 100 na duniya dangane da rahotannin kudi na 2022 na kamfanoni a yankuna daban-daban.
.
Wannan jeri na musamman ne kuma kimiyya a cikin cewa ta ƙunshi mafi kyawun kamfanonin na'urorin na'urorin lafiya a duk duniya:
Hukumar da aka jera kamfanonin kiwon lafiya daga China na ba da cikakken hoto game da matsayin China da tasiri a masana'antar na'urorin likita ta duniya.
Tushen bayanai da ƙididdigar lissafin: CIGABA DAGA CIKIN SAUKI A CIKIN SAUKI NA 202220 ga wasu manyan kungiyoyin kiwon lafiya na kasuwancin ana lissafta; Gabaɗaya bayyananne da amincin bayanan an tabbatar. (Saboda buƙatun daban-daban don kamfanoni daban-daban, lokacin kasafin kudi na kasafin kudi ba iri ɗaya bane, saboda wadannan kudaden shiga sun dace da ainihin lokaci guda.)
Don ma'anar na'urorin kiwon lafiya, ya dogara da ƙa'idodin Sin game da kulawa da gudanar da na'urorin kiwon lafiya.
Kamfanoni na Musamman: Kamfanonin Sin a wannan jeri sun hada da:
Myriad lafiya na lafiya (na shekara ta 33), jiuan likita (40th) weigocs (61st), kulawa da (67th), Unival Megicar (73th), rashin lafiya (81st), Yuyee Medical (82D), Kawa Basech (84th), Shengxiang Balibanci (81th), Ma'anar Ba'ira ), Zhende likita (93rd), WAFU BIGECHNOLOOLORD (95th), Kephi Biethechnology (96th), Shuohi Biotechnology (97th), da Lansshan na likita (100th).
A cewar 2023 Medtech Top100, kamfanonin na'urar na likita suna da halaye masu zuwa:
Rarraba kudaden shiga yana da rashin jituwa: 10% na kamfanoni a jerin kudaden shiga dala biliyan 10, da kashi 75% suna ƙasa da dala 40 na masana'antar injiniya.
Tasirin yanki na yanki a bayyane yake:
Amurka tana gida zuwa kashi 40 na kamfanonin a jerin; Matsakaicin kasuwar Medtech, karfinsa ga bidi'a ta fasaha, da kuma babban karbar sabbin kayayyaki sun ba da gudummawa ga yanayin kirkirar asali.
China ta biyo baya sakamakon kashi 17 na hedikwatar kamfanonin da aka jera; Yana da fa'ida daga tallafin manufofin ƙasar, cigaba da kasuwa da ke ci gaba, da ƙarfi a samarwa da samar da sarkar.
Of musamman bayanin sanarwa da Denmark, ƙasashe kananan ƙasashe biyu masu kamfanoni ne masu mahimmanci kuma gasa a takamaiman sassan kasuwa.
Lokaci: Dec-18-2023